Meeting
2014 ASCO Annual Meeting
A phase II randomized, placebo controlled study to evaluate the efficacy of the combination of gemcitabine, erlotinib, and metformin in patients with locally advanced or metastatic pancreatic cancer.
Authors
Johanna Wilmink
Academic Medical Center, Amsterdam, Netherlands
Johanna Wilmink , Sil Kordes , Koos Zwinderman , Ron Mathot , Cornelis J. A. Punt , Dirk Richel
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Highlights Session
Session Title
Gastrointestinal (Noncolorectal) Cancer
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Pancreatic Cancer
Clinical Trial Registration Number
NCTO1210911
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 4021)
DOI
10.1200/jco.2014.32.15_suppl.4021
Abstract #
4021
Poster Bd #
40
Abstract Disclosures
Similar Posters
Poster
2018 Gastrointestinal Cancers Symposium
A randomized phase II clinical trial of gemcitabine, oxaliplatin, erlotinib combination chemotherapy versus gemcitabine and erlotinib in previously untreated patients with locally advanced or metastatic pancreatic cancer.
First Author: Sung Hee Lim
Poster
2021 ASCO Annual Meeting
Randomized phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel combination therapy for locally advanced pancreatic cancer (JCOG1407).
First Author: Masato Ozaka
Poster
2019 Gastrointestinal Cancers Symposium
FOLFIRINOX in pancreatic cancer patients age 75 years or older.
First Author: Jonathan Mizrahi
Poster
2018 Gastrointestinal Cancers Symposium
Retrospective single center review of toxicity and efficacy of a modified FOLFIRINOX regimen in patients with locally advanced and metastatic pancreatic cancer.
First Author: Bhargavi Pulluri